U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula 2C2H5NO2.ClH
Molecular Weight 186.594
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GLYCINE HEMIHYDROCHLORIDE

SMILES

Cl.NCC(O)=O.NCC(O)=O

InChI

InChIKey=NXWPOAQQKBBSFS-UHFFFAOYSA-N
InChI=1S/2C2H5NO2.ClH/c2*3-1-2(4)5;/h2*1,3H2,(H,4,5);1H

HIDE SMILES / InChI

Molecular Formula C2H5NO2
Molecular Weight 75.0666
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Glycine (Cly) is a natural amino acid neurotransmitter that acts as a co-agonist at Glutamate [NMDA] receptors in the brain and is an activator of glycine receptors, GLRA1-3, GLRB. The abnormal Gly levels have been implicated in neuropsychiatric disorders. Alterations in Gly levels are implicated in several diseases of the central nervous system. Glycine was studied in phase II of clinical trials in patients with schizophrenia. The results have shown that using of glycine was associated with reduced symptoms with promising effect sizes and a possibility of improvement in cognitive function. Besides, glycine was also studied in clinical trials phase II in children with cystic fibrosis. The clinical, spirometric and inflammatory status of subjects with cystic fibrosis improved after just 8 weeks of glycine intake, suggesting that this amino acid might constitute a novel therapeutic tool for these patients. In addition, Gly was proposed as a biomarker for brain tumor malignancy. Glycine is a component of a nutrients mixture for peripheral administration to well-nourished mildly catabolic adult patients who require only short-term parenteral nutrition.

CNS Activity

Curator's Comment: Known to be CNS non-penetrant in rabbit. Human data not available.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Diagnostic
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Palliative
Unknown

Approved Use

Unknown
Preventing
FREAMINE III 8.5%

Approved Use

Aminosyn, Sulfite-Free, (a crystalline amino acid solution) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. SUPPLEMENTAL ELECTROLYTES, IN ACCORDANCE WITH THE PRESCRIPTION OF THE ATTENDING PHYSICIAN, MUST BE ADDED TO AMINOSYN SOLUTIONS WITHOUT ELECTROLYTES. Aminosyn can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. When administered with concentrated dextrose solutions with or without fat emulsions, Aminosyn is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where: (a) the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not be used; (b) gastrointestinal absorption of protein is impaired; (c) metabolic requirements for protein are substantially increased as with extensive burns and (d) morbidity and mortality may be reduced by replacing amino acids lost from tissue breakdown, thereby preserving tissue reserves, as in acute renal failure.

Launch Date

1971
PubMed

PubMed

TitleDatePubMed
Conversion of the ion selectivity of the 5-HT(3a) receptor from cationic to anionic reveals a conserved feature of the ligand-gated ion channel superfamily.
2001 Apr 6
Use of trifluoroperazine isolates a [(3)H]Ifenprodil binding site in rat brain membranes with the pharmacology of the voltage-independent ifenprodil site on N-methyl-D-aspartate receptors containing NR2B subunits.
2001 Jan
Substrate and inhibitor specificities for human monoamine oxidase A and B are influenced by a single amino acid.
2001 Mar 30
Patents

Sample Use Guides

Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
Route of Administration: Oral
The excess of glycine inhibits the growth of many bacteria, and it is used as a nonspecific antiseptic agent due to its low level of toxicity in animals. The MIC at which 90% of strains are inhibited for glycine was almost 2.5 mg/ml for 31 strains of H. pylori, including CLR-resistant strains.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:12:15 GMT 2023
Edited
by admin
on Fri Dec 15 15:12:15 GMT 2023
Record UNII
1KIB230SGR
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GLYCINE HEMIHYDROCHLORIDE
Common Name English
GLYCINE HYDROCHLORIDE (2:1)
Systematic Name English
BISGLYCINE HYDROCHLORIDE
Systematic Name English
DIGLYCINE HYDROCHLORIDE
Systematic Name English
Code System Code Type Description
PUBCHEM
22257257
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
ECHA (EC/EINECS)
231-305-9
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
CAS
7490-95-1
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
EPA CompTox
DTXSID60225878
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
FDA UNII
1KIB230SGR
Created by admin on Fri Dec 15 15:12:15 GMT 2023 , Edited by admin on Fri Dec 15 15:12:15 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE